A SINGLE ARM, OPEN-LABEL, LONG-TERM EFFICACY AND SAFETY STUDY OF ROMIPLOSTIM IN THROMBOCYTOPENIC PEDIATRIC SUBJECTS WITH IMMUNE THROMBOCYTOPENIA (ITP)
- Registry ID
- 20101221
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- AMGEN CANADA INC
- Start date
- 2015-06-22
- Last update
- 2014-11-04
Conditions
- IMMUNE THROMBOCYTOPENIA (ITP)
Related clinical trials
- AN INTERVENTIONAL PHASE 2, OPEN-LABEL, ONE-ARM, MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-06835375 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE PRIMARY IMMUNE THROMOBOCYTOPENIA
- A PHASE 3, MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY WITH AN OPEN-LABEL EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ORAL RILZABRUTINIB (PRN1008) IN ADULTS AND ADOLESCENTS WITH PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP)
- OPEN LABEL, ADAPTIVE DESIGN, ASCENDING, MULTIPLE-DOSE STUDY TO EVALUATE SAFETY AND EFFICACY OF BMS-986004 (ANTI-CD40L DAB) IN ADULT SUBJECTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
View on source registry